Home
Resources
Follow portfolio news
...

Unlearn raises $50m to optimise clinical research using artificial intelligence

Published on
17/4/2024
Amended on
5/11/2026
0
minute(s)
Odyssey 2021
Unlearn Raises $50M and Improves Clinical Research
Unlearn, a pioneering artificial intelligence company focused on creating digital twins* of clinical trial participants, has just announced another crucial milestone in its journey with a $50 million Series C funding round. Led by Altimeter Capital and with the participation of existing investors such as Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures and Necessary Venture Capital, this new round of funding propels Unlearn to new heights in its mission to radically transform clinical research through AI.
By
Damien Hélène
Damien Hélène
Unlearn raises $50m to optimise clinical research using artificial intelligence
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
This article has been automatically translated. We apologize per inaccuracies or translation errors.

Since its inception in 2017, Unlearn has always been at the forefront of innovation, developing AI-based solutions to overcome major challenges in clinical research. With this latest round of funding, bringing the total amount raised to over $130 million, Unlearn is positioning itself to tackle key issues such as long timelines, slow participant recruitment and patient reluctance to join clinical trials for fear of receiving a placebo.

The revolutionary approach of Unlearn, a company featured in theOdyssey Vintage Altaroc Odyssey , is based on creating personalized digital twins for each clinical trial participant, predicting their health outcomes under placebo conditions, regardless of their actual assignment. This technology enables the implementation of TwinRCTs™, highly powerful clinical trials with smaller control groups, thereby offering more patients the opportunity to benefit from experimental treatments.

By reducing the time it takes to bring new drugs and therapies to market, Unlearn paves the way for significant improvements in healthcare outcomes for all.

Dr. Charles Fisher, founder and CEO of Unlearn, emphasizes the importance of this new round of funding in pursuing the company's mission: "We are determined to overcome the obstacles and prove the value of digital twin technology. This new injection of capital will enable us not only to strengthen our team, but also to extend our capabilities to other therapeutic areas, while raising awareness of the importance of our work."

In recent years, the clinical research industry has seen the emergence of advanced solutions to its most pressing challenges. However, regulatory constraints have often impeded progress. Unlearn has successfully navigated this complex landscape by partnering with regulatory experts and gaining important qualifications, notably from the European Medicines Agency and the US Food and Drug Administration.

The company is also collaborating with biotech companies and academic institutions to accelerate the evaluation process for new treatments, paving the way for a new era of medical discovery.

*The digital twin is not a robot or a 3D body reproduction, but a data set that mirrors each human organism as closely as possible.

‍

Other content in this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
Follow portfolio news
News from the Vintage Altaroc Companies
Every two weeks, check out the latest announcements from the Vintage Altaroc companies.
Article
|
04
2026-11-04
News from the Vintage Altaroc Companies
Follow portfolio news
News from the Vintage Altaroc Companies
Every two weeks, check out the latest announcements from the Vintage Altaroc companies.
Article
|
22
2026-10-22
From elite sports to medical AI: what's new in the portfolio Altaroc
Follow portfolio news
From elite sports to medical AI: what's new in the portfolio Altaroc
Software adopted by every NFL team, AI agents that have already conducted 180 million interactions with patients, and a platform used by nearly one in five Fortune 500 companies. A look at nine acquisitions by the " Vintage "Odyssey over the past three months.
Article
|
19
2026-10-19
Follow portfolio news
News from the Vintage Altaroc Companies
Every two weeks, check out the latest announcements from the Vintage Altaroc companies.
Article
|
08
2026-10-08
A triptych illustrating the sports, health, and business sectors for corporate news from Vintage Altaroc
Follow portfolio news
News from the Vintage Altaroc Companies
Every two weeks, check out the latest announcements from the Vintage Altaroc companies.
Article
|
23
2026-09-23
Interview with Raul Villar, CEO of Optro
Follow portfolio news
Interview with Raul Villar, CEO of Optro
Raul Villar Jr. unveils his platform's global growth strategy, powered by AI, and his partnership with Hg
Video
|
13
2026-08-13
Interview with Chris Maclin, CEO of Empyrean
Follow portfolio news
Interview with Chris Maclin, CEO of Empyrean
In Boston, Chris Maclin, CEO of Empyrean, explains how his technology platform protects banks and modernizes risk management
Video
|
29
2026-05-29
Interview with Ian Drysdale, CEO of One Inc.
Follow portfolio news
Interview with Ian Drysdale, CEO of One Inc.
Learn about the career of Ian Drysdale, CEO of One Inc, a specialist in payment infrastructure for the insurance industry.
Video
|
09
2026-04-09
Interview with Daniel Baker, CEO of Healthdrive
Follow portfolio news
Interview with Daniel Baker, CEO of Healthdrive
In Boston, Daniel Baker, CEO of HealthDrive, shares his vision for sustainable growth with a human impact.
Video
|
29
2026-01-29
Interview Jeff Wessler - CEO Heartbeat
Follow portfolio news
Interview Jeff Wessler - CEO Heartbeat
Dr. Jeff Wessler, founder of Heartbeat Health, pioneer of virtual-first cardiology in the United States
Video
|
25
2025-11-25
Special report - Focus on the United States: 10 hypergrowth companies
Follow portfolio news
Special report - Focus on the United States: 10 hypergrowth companies
As the historic driving force behind global private equity, the United States is home to some of the most dynamic companies on the planet. This report highlights 10 hyper-growth American companies, backed by private equity, at the heart of key economic sectors.
File
|
12
2024-03-12
No articles in this category yet.
Welcome to Altaroc
In accordance with applicable regulations, we ask that you complete your profile. This step is required to access the content and services offered on our websites.
Please fill out your profile to access the site
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
YOUR INVESTOR PROFILE
Financial intermediary or professional investor
Financial advisors, wealth managers, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced investor or Altaroc investor
Private investors who have already invested with Altaroc or who have a minimum investment capacity of €100,000.
Private investors who have previously invested in Altaroc who have a minimum investment capacity of 200,000 euros.
Non-professional (retail) investor
Individual investors with an investment capacity below €100,000.
Retail investors with an investment capacity of less than 200,000 euros.
Institutional investor
Pension funds, retirement schemes, asset management companies, and single-family offices.
Select your language and investor profile to continue
Select your investor profile to continue
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.